LETTER TO THE EDITORS

Lacosamide and myoclonic seizures: what is the risk of aggravation?

Magdalena Bosak¹, Kamil Wężyk², Agnieszka Słowik¹

¹Collegium Medicum, Jagiellonian University of Krakow, Krakow, Poland
²University Hospital in Krakow, Poland

Key words: lacosamide, myoclonic seizures, aggravation, exacerbation

To the Editors:

Lacosamide (LCM), a novel antiseizure medication (ASM), is believed to exert its anticonvulsant action through selective enhancement of slow inactivation of voltage-gated sodium channels.

LCM is indicated for the treatment of focal seizures, and has recently been demonstrated to be efficacious as an adjunctive therapy for primary generalised tonic-clonic seizures (GTCS) [1]. Genetic generalised epilepsies (GGEs) comprise 15–20% of all epilepsies, and are usually easy to treat with broad-spectrum ASM [2, 3]. Myoclonic and absence seizures in GGEs seem to be more vulnerable to aggravation by some ASMs. The older sodium channel blockers (SCBs) such as phenytoin (PHT), carbamazepine (CBZ), oxcarbazepine (OCBZ), and lamotrigine (LTG), may worsen myoclonic seizures [2].

Here we report a case series of patients who experienced an exacerbation of generalised myoclonic seizures following initiation of LCM in light of the existing literature.

Case 1

A 47-year-old woman presented to the epilepsy clinic with an increased number of seizures. Her epilepsy had started with myoclonic jerks in the morning at age 13. She had been successfully treated for five years with phenobarbital (PB), then was switched to CBZ for unknown reasons. On CBZ, she experienced absence and myoclonic seizures once per week and generalised tonic-clonic seizures (GTCS) every few years. LCM was added to CBZ three years ago, with a deterioration in seizure control. On LCM 350 mg/day (150 mg in the morning, 200 mg at night) and CBZ-CR 1,000 mg/day she had daily myoclonic seizures and up to three GTCSs per month. Electroencephalography (EEG) showed background slowing with beta waves excess (she took alprazolam) and generalised polyspike and slow wave discharges (GPSWD) (Fig. 1A). Juvenile myoclonic epilepsy (JME) was diagnosed, LCM had been gradually discontinued, and valproate (VPA) was initiated. On the subsequent visit, while taking CBZ-CR 1,000 mg/day and VPA 1,500 mg/day, she reported no absences, myoclonus or GTCS. EEG revealed GPSWD with normal background (Supp. Fig. 1). CBZ had been gradually withdrawn. EEG taken seven months later on VPA 1,500 mg/day showed normal background without epileptiform discharges (Supp. Fig. 2). The patient was seizure free.

Case 2

A 34-year-old woman presented with a history of refractory JME that had begun at age 14. She had been treated with VPA, LTG, LEV, PB, topiramate (TPM), but without ever achieving seizure control. On VPA 1,000 mg/day, LTG 150 mg/day, and TPM 400 mg/day she experienced GTCS bimonthly and myoclonic seizures once per week. Because she planned pregnancy, VPA and TPM were gradually withdrawn and LEV 2,000 mg/day introduced, with no apparent change in seizure control. She delivered a healthy baby by caesarean section. Given its confirmed efficacy as an add-on treatment of primary GTCS, LCM was added to the treatment regimen (LTG 150 mg/day, LEV 2,000 mg/day). Two weeks after initiating treatment with LCM, the frequency of myoclonic seizures increased, reaching one or two every day while taking 100 mg BID.

Address for correspondence: Magdalena Bosak, Collegium Medicum, Jagiellonian University of Krakow, Krakow, Poland, e-mail: magdalena.bosak@uj.edu.pl
Figure 1. EEG in patients with myoclonic seizures exacerbation on lacosamide
A. Patient 1: background slowing with beta waves excess and polyspike and slow wave discharges; patient had experienced three generalised tonic-clonic seizures on previous day; B. Patient 2: polyspike and wave discharges in drowsiness; C. Patient 3: multiple polyspike and wave discharges during photostimulation.
EEG revealed multiple GPSWD enhanced by sleep (Fig. 1B). The frequency of GTCS did not change. LCM was discontinued after two months and myoclonus frequency decreased significantly to once per week. Follow-up EEG showed no epileptiform discharges (Supp. Fig. 3).

Case 3

This 27-year-old woman with juvenile absence epilepsy (JAE) had unremarkable family and medical history. At age 13, she started having weekly absence seizures and occasional GTCS. She continued to have seizures on CBZ. TPM controlled only GTCS and caused cognitive side effects. At age 21, she was started on VPA 1,000 mg/day, with complete seizure remission. EEG showed no epileptiform discharges (Supp. Fig. 4). Seven years later, the patient was planning pregnancy. VPA was discontinued and the patient was switched to LTG and LEV. On LTG and LEV in mono- and polytherapy she experienced monthly GTCS and intolerable side effects. LEV and LTG were gradually withdrawn, and treatment with LCZ started at a dose of 50 mg/day, increased by 50 mg each week to 100 mg BID, and continued for one year. On LCZ, she experienced a relapse of daily absences and a new occurrence of weekly myoclonic seizures, with no deterioration in GTCS control. EEG revealed multiple GPSWD enhanced by photostimulation (Supp Fig. 3B). Discontinuation of LCZ and the introduction of low doses of LTG and LEV restored the patient to her previous clinical condition. Absences, myoclonic seizures and epileptiform discharges on EEG resolved, with GTCS occurring once per month (Supp. Fig. 5).

We identified six articles regarding myoclonus being made worse by LCZ in the literature. A woman with refractory JME who was started on LCZ experienced a subsequent increase of myoclonic seizures, and myoclonus resolved after LCZ withdrawal [4]. Another study reported the case of a patient with GTCS who experienced a new occurrence of myoclonic seizures after switching from VPA to LCZ. Myoclonic seizures stopped after LCZ withdrawal [5]. Italian authors described a young female with focal epilepsy due to focal cortical dysplasia. The addition of LCZ to CBZ resulted in an occurrence of epileptic negative myoclonus, which resolved after CBZ dose reduction without any change in LCZ dosage [6]. In a case series of nine patients with refractory GTCS, one patient with JAE experienced absence and myoclonic status epilepticus after the introduction of LCZ [7]. In an open label study assessing the safety of LCZ in the treatment of uncontrolled primary GTCS, one patient reported worsening of myoclonic seizures while taking LCZ; this resolved without LCZ dosage change [8]. In the study by Vossler et al. among patients with myoclonic seizures, 8.5% on LCZ had a ≥ 50% increase in myoclonus. Furthermore, one patient had a new occurrence of myoclonic seizures [1].

In total, we have identified 14 cases of myoclonus aggravation or induction: 11 cases were extracted from the literature, and three patients were seen at our centre. All but one suffered from generalised epilepsy. Additionally, some patients experienced GTCS or absence worsening and one suffered from status epilepticus. However, it should be pointed out that in our three cases LCZ was added to other SCBs (LTG or CBZ), and the exacerbation of myoclonus may have been synergised/facilitated by the co-medication with two SCBs.

Our report suggests that LCZ may have the potential to worsen or to induce fresh myoclonic seizures. It should be used with caution in GGEs with multiple seizure types. Further studies are needed to evaluate the risk of myoclonus aggravation/induction with lacosamide.

References: